These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38126188)

  • 1. Comprehensive mapping of mutations in TDP-43 and α-Synuclein that affect stability and binding.
    Alamri SH; Haque S; Alghamdi BS; Tayeb HO; Azhari S; Farsi RM; Elmokadem A; Alamri TA; Harakeh S; Prakash A; Kumar V
    J Biomol Struct Dyn; 2023 Dec; ():1-13. PubMed ID: 38126188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prion-like C-Terminal Domain of TDP-43 and α-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils.
    Dhakal S; Wyant CE; George HE; Morgan SE; Rangachari V
    J Mol Biol; 2021 May; 433(10):166953. PubMed ID: 33771571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational investigation on the conformational dynamics of C-terminal truncated α-synuclein bound to membrane.
    Das D; Mattaparthi VSK
    J Biomol Struct Dyn; 2024 Feb; ():1-13. PubMed ID: 38321955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Microplate-Based Approach to Map Interactions between TDP-43 and α-Synuclein.
    Jamerlan AM; An SSA
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.
    St-Amour I; Turgeon A; Goupil C; Planel E; Hébert SS
    Acta Neuropathol; 2018 Feb; 135(2):249-265. PubMed ID: 29134321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights into the structural changes induced by disease-associated mutations in TDP-43: a computational approach.
    Sharma A; Dey P
    J Biomol Struct Dyn; 2023; 41(12):5624-5634. PubMed ID: 35751132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain.
    Conicella AE; Zerze GH; Mittal J; Fawzi NL
    Structure; 2016 Sep; 24(9):1537-49. PubMed ID: 27545621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TDP-43 in amyotrophic lateral sclerosis - is it a prion disease?
    Ludolph AC; Brettschneider J
    Eur J Neurol; 2015 May; 22(5):753-61. PubMed ID: 25846565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of thermal unfolding simulations of RNA recognition motifs (RRMs) of TAR DNA-binding protein 43 (TDP-43).
    Prakash A; Kumar V; Meena NK; Hassan MI; Lynn AM
    J Biomol Struct Dyn; 2019 Jan; 37(1):178-194. PubMed ID: 29279008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies.
    Kokoulina P; Rohn TT
    Neurodegener Dis; 2010; 7(4):243-50. PubMed ID: 20551689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulins modulate liquid-liquid phase separation and aggregation of the prion-like C-terminal domain of the neurodegeneration-associated protein TDP-43.
    Bhopatkar AA; Uversky VN; Rangachari V
    J Biol Chem; 2020 Feb; 295(8):2506-2519. PubMed ID: 31911437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis.
    Toyoshima Y; Takahashi H
    Neuropathology; 2014 Feb; 34(1):77-82. PubMed ID: 23889603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALS-causing cleavages of TDP-43 abolish its RRM2 structure and unlock CTD for enhanced aggregation and toxicity.
    Wei Y; Lim L; Wang L; Song J
    Biochem Biophys Res Commun; 2017 Apr; 485(4):826-831. PubMed ID: 28257838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational investigation on the effect of Oleuropein aglycone on the α-synuclein aggregation.
    Borah P; Sanjeev A; Mattaparthi VSK
    J Biomol Struct Dyn; 2021 Mar; 39(4):1259-1270. PubMed ID: 32041489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and biophysical characterization of pathological aggregation of amyloid proteins.
    Long H; Zeng S; Sun Y; Liu C
    Biophys Rep; 2022 Feb; 8(1):42-54. PubMed ID: 37287686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP.
    Feneberg E; Charles PD; Finelli MJ; Scott C; Kessler BM; Fischer R; Ansorge O; Gray E; Talbot K; Turner MR
    Brain Pathol; 2021 Jul; 31(4):e12923. PubMed ID: 33300249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurons with Cat's Eyes: A Synthetic Strain of α-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions.
    De Giorgi F; Abdul-Shukkoor MB; Kashyrina M; Largitte LA; De Nuccio F; Kauffmann B; Lends A; Laferrière F; Bonhommeau S; Lofrumento DD; Bousset L; Bezard E; Buffeteau T; Loquet A; Ichas F
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.
    Johnson BS; McCaffery JM; Lindquist S; Gitler AD
    Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6439-44. PubMed ID: 18434538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TDP-1/TDP-43 potentiates human α-Synuclein (HASN) neurodegeneration in Caenorhabditis elegans.
    Shen L; Wang C; Chen L; Leung KL; Lo E; Lakso M; Wong G
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165876. PubMed ID: 32531261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational investigation on the effect of the peptidomimetic inhibitors (NPT100-18A and NPT200-11) on the α-synuclein and lipid membrane interactions.
    Das D; Bharadwaz P; Mattaparthi VSK
    J Biomol Struct Dyn; 2023 Sep; ():1-12. PubMed ID: 37768058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.